MentionFox
Home › Executive changes › Aptevo Therapeutics Inc.
Leadership changes · APVO · SEC Form 8-K, Item 5.02

Leadership changes at Aptevo Therapeutics Inc. (2026)

Before you join, sell to or invest in Aptevo Therapeutics Inc.

MentionFox check on Aptevo Therapeutics Inc.: only 1 source on file so far (checked 14 November 2026). Run a full check before you rely on it. mentionfox.com/c/executive-changes/aptevo-therapeutics

Check Aptevo Therapeutics Inc. before you join, sell or invest Free, no sign-up: every record on file, each linked to its source.

What do you want to do about Aptevo Therapeutics Inc.?

Who joined and who left Aptevo Therapeutics Inc. (APVO)? 2 appointments and 1 departure reported on 2026-02-03, each cited to the company's own filing.

Jeff Lamothe was named President and Chief Executive Officer of Aptevo Therapeutics Inc., succeeding Marvin L. White. As of November 14, 2026, Aptevo Therapeutics Inc. has reported one leadership change filing to the SEC under Item 5.02 of Form 8-K, on February 3, 2026, naming 2 appointments and 1 departure (Form 8-K, February 3, 2026).

29 companies changed executives this week, 1 had other signals.

Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.

ONITY GROUP INC.announced the departure of its Chief Investment Officer
Adicet Bio, Inc.announced the departure of its Director
MAMMOTH ENERGY SERVICES, INC.announced the departure of its Chief Operating Officer
CERENOME, INC.named a new Director
Cohen & Co Inc.named a new Chief Executive Officer
Check one company free All companies that changed executives this week

YA II PN, Ltd. also filed stake reports on 14 other companies ↓

Sell to companies like Aptevo Therapeutics Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.

Opens in a new tab. No signup.

Key facts

  • · In / out: Out · Person: Marvin L. White · Role: President and Chief Executive Officer · Effective: 2026-04-01 · 8-K, 2026-02-03
  • · In / out: In · Person: Jeff Lamothe · Role: Director · 8-K, 2026-02-03
  • · In / out: In · Person: Jeff Lamothe · Role: President and Chief Executive Officer · 8-K, 2026-02-03
Changes3
In (appointed)2
Out (departing)1
Latest filing2026-02-03

Aptevo Therapeutics Inc. reported a change among its directors and officers to the SEC on Form 8-K, Item 5.02, on 2026-02-03. It names 2 people, with 2 appointments and 1 departure. Every row below is cited to the filing it comes from, and this page adds each new change as Aptevo Therapeutics Inc. files it.

Also on the record for Aptevo Therapeutics Inc.

DateRecordFigureOur pageSource
November 12, 2026Stake report, Schedule 13G/A, by Ayrton Capital LLC3.72% of the class5%+ stakesSource
August 26, 2026Form D, private offering$3.47M soldForm D pageSource
August 14, 2026Stake report, Schedule 13G/A, by CVI Investments, Inc.6.3% of the class5%+ stakesSource
June 22, 2026Stake report, Schedule 13G, by NIOWAVE, INC.12.2% of the class5%+ stakesSource
February 17, 2026Stake report, Schedule 13G/A, by CVI Investments, Inc.8.2% of the class5%+ stakesSource
February 17, 2026Stake report, Schedule 13G/A, by Point72 Asset Management, L.P.—5%+ stakesSource
November 7, 2025Stake report, Schedule 13G/A, by BANK OF AMERICA CORP /DE/—5%+ stakesSource
October 6, 2025Stake report, Schedule 13G, by BANK OF AMERICA CORP /DE/15% of the class5%+ stakesSource
September 17, 2025Stake report, Schedule 13G, by Point72 Asset Management, L.P.9.1% of the class5%+ stakesSource
August 14, 2025Stake report, Schedule 13G/A, by CVI Investments, Inc.9.9% of the class5%+ stakesSource
August 14, 2025Stake report, Schedule 13G/A, by L1 Capital Global Opportunities Master Fund, Ltd.4.99% of the class5%+ stakesSource
August 13, 2025Stake report, Schedule 13G, by Ayrton Capital LLC10% of the class5%+ stakesSource

Selling to them or working with them? See who runs Aptevo Therapeutics Inc. now and the warning signs.

Free to see. No signup.

Keep reading

More on Aptevo Therapeutics Inc. and the records around it.

Aptevo Therapeutics Inc. elsewhere on the record

Companies that share a holder

Want the whole picture on Aptevo Therapeutics Inc.?

Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)

A Full Report on Aptevo Therapeutics Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.

What the Full Report on Aptevo Therapeutics Inc. covers

  1. The Short Answer

  2. Which Company This Is

  3. What They Do, And How The Money Works

  4. Who Runs It, And How To Reach Them

  5. The Money: Funding, Valuation, Runway

  6. Who Pays Them, And Who They Are Up Against

  7. Warning Bells

  8. Sources

    13 cited sources found

Plus the sections for what you are deciding, which you pick after ordering.

See a sample report

First screen of a real sample Full Report on EchoStar: the verdict, 17 sections, 63 cited sources, built 2026-10-21A real finished report, first screen. Opens in a new tab.

The newest 12 of 14 records.

Timeline

FiledIn / outPersonRoleEffectiveSource
2026-02-03OutPresident and Chief Executive Officer2026-04-018-K, 2026-02-03
2026-02-03InDirector8-K, 2026-02-03
2026-02-03InPresident and Chief Executive Officer8-K, 2026-02-03

Why did they leave? What the filings say

For each named departure below, the sentence from the company's own filing that gives a reason, word for word. Where a filing gives none, it says so here; nothing is inferred.

Who leads Aptevo Therapeutics Inc., as last reported?

For each role that changed in the filings below, the most recent change reported. A role that did not change in these filings is not listed.

Selling to Aptevo Therapeutics Inc.?

New leaders reset buying decisions — get the Full Report on Aptevo Therapeutics Inc.: who runs it, how the money works and what to watch, every claim linked to its source.

Get the Full Report

Watch Aptevo Therapeutics Inc. (free up to 3)

Hiring for a seat like this?

Find people with the same kind of experience as the President and Chief Executive Officer at Aptevo Therapeutics Inc., with the record behind each one.

Find candidates like President and Chief Executive Officer at Aptevo Therapeutics Inc.

Every change, in the filing's words

Filed 2026-02-03 · 8-K

Departing: Marvin L. White, President and Chief Executive Officer, effective 2026-04-01

On January 30, 2026, Marvin L. White notified Aptevo Therapeutics Inc. (the "Company") of his intent to retire as the Company's President and Chief Executive Officer, effective as of April 1, 2026 (the "Transition Date").

Appointed: Jeff Lamothe, Director

In addition, the Board has appointed Mr. Lamothe to serve as a Class III director of the Company to hold office until the 2028 annual meeting of stockholders of the Company and a member of the Executive Committee of the Board effective as of the Transition Date.

Appointed: Jeff Lamothe, President and Chief Executive Officer

In his capacity as President and Chief Executive Officer, Mr. Lamothe will serve as the Company's principal executive officer.

Also stated in this filing

  • On February 3, 2026, the Company announced that effective as of the Transition Date, Mr. White will transition to the role of Executive Chair of the Board, and Jeff Lamothe, the Company's current Chief Operating Officer, will assume the role of President and Chief Executive Officer of the Company.
  • Accordingly, the size of the Board will be increased from six directors to seven directors effective as of the Transition Date.
  • As Executive Chair, Mr. White will work closely with Mr. Lamothe and the executive team to provide mentorship and continuity and support the Company's long-term growth.
  • John E. Niederhuber, M.D., currently serving on the Board and as Chairman of the Board, will serve as Lead Independent Director effective as of the Transition Date.
  • Mr. Lamothe, age 60, has served as the Company's Executive Vice President and Chief Operating Officer since March 2023, previously Executive Vice President and Chief Financial Officer since February 2022 and Senior Vice President and Chief Financial Officer since July 2016.
  • Mr. Lamothe previously served as Emergent's Vice President Finance, Biosciences Division.
  • Mr. Lamothe assumed this role in February 2014 when Emergent concluded the acquisition of Cangene Corporation ("Cangene"), where he was Chief Financial Officer.
  • Mr. Lamothe assumed the role of Chief Financial Officer of Cangene in August 2012.

Tools for this story

Each opens in a new tab, filled in for Aptevo Therapeutics Inc.. With no account yet, you sign up free and land on the result.

Where this comes from

A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.

Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.

Not for employment, credit or tenancy decisions. MentionFox research is for sales, partnership and investor research. Permitted use

Cite this page

Permanent URL: https://mentionfox.com/executive-changes/aptevo-therapeutics
Last updated 2026-11-14
Primary record: SEC filing 1 · SEC filing 2 · SEC filing 3 · SEC filing 4
Aptevo Therapeutics Inc. names Jeff Lamothe CEO (2026). MentionFox, 2026-11-14. https://mentionfox.com/executive-changes/aptevo-therapeutics